alfaglukosidisidosten

Alpha-glucosidase inhibitors are a class of oral antidiabetic drugs used in the management of type 2 diabetes. They work by slowing down the digestion of carbohydrates in the small intestine. Specifically, they inhibit the action of alpha-glucosidase enzymes, which are responsible for breaking down complex carbohydrates into simple sugars like glucose. This delayed breakdown leads to a more gradual absorption of glucose into the bloodstream after a meal, resulting in lower postprandial (after-meal) blood glucose levels.

These medications are typically taken with the first bite of each main meal. Common side effects are gastrointestinal in nature, including bloating, gas, diarrhea, and abdominal pain, as these are a direct consequence of undigested carbohydrates reaching the large intestine. Alpha-glucosidase inhibitors are generally not associated with weight gain and have a low risk of hypoglycemia (low blood sugar) when used as monotherapy. They are often prescribed in combination with other diabetes medications. Examples of alpha-glucosidase inhibitors include acarbose and miglitol. Their effectiveness in reducing HbA1c levels can vary, but they are a useful option for individuals seeking to improve glycemic control, particularly by targeting postprandial hyperglycemia.